rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PRQR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Raymond James reiterates Strong Buy on ProQR stock, $10 target
      Nov 13Investing.comPRQRRJF
      Citizens reiterates ProQR Therapeutics stock rating on pipeline data
      Nov 13Investing.comPRQR
      ProQR Therapeutics NV earnings beat by €0.01, revenue topped estimates
      Nov 12Investing.comPRQR
      ProQR Therapeutics N.V. (PRQR) Presents at TIDES Europe 2026 - Slideshow (NASDAQ:PRQR) 2026-11-04
      Nov 4Seeking AlphaPRQR
      ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

      ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary sessi...

      Oct 28Business InsiderPRQR
      Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)

      Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailPRQRSGMT
      ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

      ProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on

      Oct 2Yahoo FinancePRQR
      H.C. Wainwright cuts ProQR stock price target on execution risks
      Oct 1Investing.comPRQR
      Citizens reiterates ProQR stock rating on biliary atresia data
      Oct 1Investing.comPRQR
      ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-09-30

      2026-09-30. The following slide deck was published by ProQR Therapeutics N.V.

      Sep 30Seeking AlphaPRQR
      ProQR names AI executives as clinical data nears
      Sep 23Investing.comPRQR
      Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical
      Sep 10BarchartPRQRRYTM
      ProQR doses first participant in AX-0811 phase 1 trial
      Sep 9Investing.comPRQR
      ProQR at Cantor conference: RNA editing pipeline gains speed
      Sep 9Investing.comPRQR
      ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

      ProQR Therapeutics (PRQR) said Wednesday it has dosed the first participant in a phase 1 trial of AX

      Sep 9Yahoo FinancePRQR
      ProQR to Participate in Upcoming Investor Conferences in September 2026

      LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage ...

      Sep 2Business InsiderPRQR
      ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR)

      Buy ProQR Therapeutics N.V.: Axiomer RNA editing shows strong phase 1 proof-of-concept for biliary atresia; key 2026–27 catalysts ahead. Click to read more.

      Aug 21Seeking AlphaPRQR

      This is the newest page. Registered accounts read further back.